InnoCan Pharma Stock Price

CNSX:INNOCA$49.7mPharmaceuticals & Biotech

INNO Share Price Performance

INNO Community Fair Values

RenovoRx
ST
Stock_Research_Today
Community Contributor
Revolutionizing Cancer Treatment
A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.
View narrative
US$4.20
FV
66.7% undervalued intrinsic discount
371.30%
Revenue growth p.a.
11users have liked this narrative
3users have commented on this narrative
109users have followed this narrative
about 1 month ago author updated this narrative
Your Fair Value
CA$
Current Price
CA$0.1796.8% undervalued intrinsic discount
Growth estimate over
Annual revenue growth rate
%/yr
Decrease
Increase
Advanced

View all narratives

Recent INNO News & Updates

InnoCan Pharma Corporation Competitors

View more competitors

InnoCan Pharma Corporation Key Details

Last Reported Earnings

Mar 31, 2025

Yearly revenue growth

n/a

Earnings per share (EPS): -0.0022
Gross Margin: 89.61%
Net Profit Margin: -2.13%
Debt/Equity Ratio: 18.9%

View full report ›

Canadian Market Performance

7 Days: 0.4%
3 Months: 7.8%
1 Year: 15.7%
Year to Date: 6.1%

In the last week, the market has stayed flat, however the Materials sector stood out, gaining 4.1%. More promisingly, the market is up 16% over the past year. Earnings are forecast to grow by 12% annually. Market details ›

🤖 A.I. Enters the “Show Me The Money” Phase

Richard Bowman

May 2025

The AI frenzy of 2023 and 2024 has cooled down and entered the "show me the money" phase. Earnings season has shed a lot of light on where we stand. So it’s time for an update on the industry and a look at the companies successfully deploying AI, monetizing it, and the potential opportunities for investors.

Last Week

InnoCan Pharma Stock Price

INNO Share Price Performance

INNO Community Fair Values

Revolutionizing Cancer Treatment

Recent INNO News & Updates

First quarter 2025 earnings released: US$0.002 loss per share (vs US$0.007 loss in 1Q 2024)

InnoCan Pharma Corporation, Annual General Meeting, Jun 26, 2025

Innocan Pharma Corporation First Granted Patent in Mexico for Its Topical Pain Relief

InnoCan Pharma Corporation announced that it has received CAD 0.214839 million in funding

Innocan Pharma Corporation Announces Divisional Application for Its Liposomal Liposome-Based CBD Technology Patent

Full year 2024 earnings released: US$0.007 loss per share (vs US$0.018 loss in FY 2023)

InnoCan Pharma Corporation announced that it has received $1 million in funding

InnoCan Pharma Corporation Competitors

🤖 A.I. Enters the “Show Me The Money” Phase

🧬 The Convergence of Genomic Medicine and AI Drug Discovery